Company,Total_Links,Text_Length_Characters,Extraction_Date,Status
GLENMARK,5,1295,2025-08-21 21:41:18,Completed

EXTRACTED_LINKS
Link_Number,URL
Link_1,"https://www.angelone.in/news/share-market/glenmark-pharma-to-launch-generic-adhd-drug-in-us-market-by-may-2025#:~:text=Glenmark%20Pharma%20to%20Launch%20Generic,Open%20Demat%20AccountLogin"
Link_2,"https://glenmarkpharma.com/media/newsroom/#:~:text=Glenmark%20Pharma%20Reports%20Q4%20&%20FY25,10%20MAR%202025%20%7C%20READ%20MORE"
Link_3,"https://www.businesstoday.in/markets/stocks/story/glenmark-pharmaceuticals-shares-in-focus-on-drug-update-to-treat-multiple-myeloma-474801-2025-05-06#:~:text=refractory%20multiple%20myeloma.%22-,IGI%20reported%20that%20it%20has%20recently%20wrapped%20up%20the%20dose,before%20making%20any%20investment%20decisions."
Link_4,"https://www.stockinsights.ai/in/GLENMARK/announcement/product-launches-20250416-08e#:~:text=Glenmark%20Pharmaceuticals%20Inc.%2C%20USA%20will,million%20as%20of%20February%202025."
Link_5,"https://www.capitalmarket.com/markets/news/hot-pursuit/Glenmark-Pharma%E2%80%99s-US-arm-to-launch-Micafungin-injection-in-the-US-market/1631606#:~:text=Glenmark%20Pharma's%20US%20arm%20to%20launch%20Micafungin,Vial)%2C%20in%20the%20U.S.%20market%20this%20September."

EXTRACTED_TEXT_CONTENT
Content_Type,Content
Complete_Text,"US market entry for generic ADHD drug:Glenmark's US arm, Glenmark Pharmaceuticals Inc., was set tolaunch generic Adderall tabletsfor the treatment of ADHD in the US market in May 2025. This launch aimed to address shortages of this highly prescribed medication and targeted a market with annual sales of approximately $421.7 million as of February 2025, according to IQVIA sales data.

Launch of other generic products:On April 1, 2025, Glenmark Pharmaceuticals Inc. also launchedVancomycin Hydrochloride for Injection USP. This suggests a continued focus on expanding its presence in the US generics market.

Ongoing clinical trial for multiple myeloma drug:Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark, was conducting a Phase 1 clinical trial for amultiple myeloma drug, ISB 2001. Initial results from the dose-escalation phase showed promising response rates and a favorable safety profile. These results were slated for presentation at the June 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Note: This information is specific to May 1, 2025. More recent developments may have occurred since then. Additionally, some articles in the search results mention planned product launches in the future (e.g., June 2025), which are included here to provide context."
